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Abstract Estrogen has been known to reduce the develop-
ment of Alzheimer’s disease (AD). However, exact mecha-
nisms are not clear. We investigated whether estrogen can
increase amyloid-beta (Aβ) degradation and affects Aβ-
induced memory impairment in an estrogen deficiency model.
Estrogen receptor alpha (ERα) knockout mice and wild-type
mice were intracerebroventricular (ICV) infused with Aβ
(300 pmol) for 2 weeks. Cognitive function was then assessed
by the Morris water maze test and passive avoidance test. In
addition, Western blot analysis, immunostaining, immunoflu-
orescence staining, ELISA, and enzyme activity assays were
used to examine the degree of Aβ deposition in the brains of
ERα knockout mice. In our present study, Aβ was accumu-
lated more in the ERα knockout mice brain and greatly
worsened memory impairment and glial activation as well as
neurogenic inflammation. These results suggest that estrogen
may protect memory impairment by stimulating the degrada-
tion of Aβ and down-regulate neurogenic inflammation as
well as amyloidogenesis.
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Introduction
Estrogen is important in the maintenance of normal brain
function. It interacts with many different receptors including
alpha and beta estrogen receptors, both of them highly
expressed in the hippocampus and cortex, the two brain
regions most implicated in the develop of Alzheimer’s
disease (AD) [1]. Reduced estrogen levels due to aging
increases the risk of AD [2]. The Women’s Health
Initiative found that estrogen therapy on cognitive func-
tion for post-menopausal women is no longer beneficial
for treatment [3, 4]. However, recent data indicate that
estrogen therapy may be effective if treated during the
perimenopausal period [5]. It was also found that estro-
gen is effective in lowering the level of brain amyloid-
beta (Aβ), a causing factor for the development of AD
in ovariectomized transgenic mice that overexpress Aβ [6].
Estrogen was also reported to reduce the generation of Aβ
peptides in cells and neurons [7]. Thus, the lowering
effect of estrogen on Aβ levels in the brain could be a
possible mechanism of its memory improving effect.
However, clear mechanisms of how estrogen lowers Aβ
levels are not defined.
Neprilysin is thought to be the primary Aβ-degrading
enzyme in the brain because degradation of radiolabeled
synthetic Aβ42 in rat brain is largely inhibited by the
neprilysin inhibitor, phosphoramidon. Neprilysin degrades
both monomeric and oligomeric forms of Aβ40 and Aβ42 in
intracellular and extracellular compartments of the brain [8].
Moreover, the levels of neprilysin mRNA and protein are
lower in the hippocampus and temporal gyrus of AD patients
[9, 10]. Neprilysin activity is also lower in the hippocampus,
cerebellum, and caudate of ovaritectomized rats than in non-
ovariectomized rats, and this effect can be reversed by exog-
enous 17β-estradiol [11]. Furthermore, two functional estro-
gen response elements (EREs) were identified in the
neprilysin gene, which bind estrogen receptor alpha (ERα)
and ERβ and thus stimulate ER-dependent gene expression
[12]. These data provide insight into the positive effects of
estrogen on neprilysin activity in the brain and thus affect Aβ
levels for improving cognitive performance in menopausal
women.
There has been a significant association between ex-
pressions of ERα or ERβ and memory function.
However, ERα is more functional for the etiology of
memory, and ERα-mediated behaviors are more sensi-
tized to estrogen in humans and mice [12]. In this
study, we investigated whether the knockout of ERα
could down-regulate neprilysin and other Aβ-degrading
enzyme expressions and activities, thus diminishing Aβ-
scavenging activity leading to the enhancement of neu-
ronal cell death and memory impairment in Aβ42-in-
fused ERα knockout mice.
Methods
Aβ1–42-Infused ERα Knockout Mice
ERα knockout mice were purchased from The Jackson
Laboratory (Bar Harbor, Maine, USA). All of the experimen-
tal procedures were approved by the Animal Care and Use
Committee (IACUC) of Chungbuk National University
(approval number: CBNUA-144-1001-01). Four experi-
mental groups of mice (n=8) were studied: the C57BL/6
wild-type (control) group (saline-infused=8, Aβ-infused=8)
and the ERα knockout mice (saline-infused=8, Aβ-infused=
8). All were female weighing 24–28 g (age 8–10 weeks old) at
the time of exposure. ERα knockout mice grow and reproduce
normally with no obvious phenotypic difference from the wild
type. All mice were housed in a room that was automatically
maintained at 21–25 °C and relative humidity (45–65 %) with
a controlled light–dark cycle. The lights were on at 0600 h
until 1800 h (KST).
The infusion model was adapted from previous work on
the mice infusion model [13]. The anesthetized mice were
placed in a sterotaxic instrument, and catheters were attached
to an osmotic mini-pump (Alzet 1002, ALZA, Mountain
View, CA, USA) and brain infusion kit 1 (Alzet kit 3–5 mm,
ALZA, Mountain View, CA, USA) which were implanted
according to the following coordinates: mouse (unilaterally)
−1.0 mm anterior/posterior, +0.5 mm medial/lateral, and
−2.5 mm dorsal/ventral. The pump contents were released
over a period of 2 weeks consisting of 300 pmol aggregated
(the lyophilized peptide of Aβ1–42 is dissolved in DW and
incubated at 37 °C for 48 h) Aβ1–42 (Bachem Chemical,
Kashiwa St, Torrance, CA, USA) dissolved in sterile saline
(0.9 % NaCl) for each pump. The pump of the control group
contained saline (0.9 % NaCl) for each pump.
Morris Water Maze Test
The Morris water maze test is a widely accepted method for
examining cognitive function and was used in the present
study as previously described [14]. Briefly, a circular plastic
pool (height 35 cm and diameter 100 cm) was filled with
water (plus white dye) maintained at 22–25 °C. An escape
platform (height 14.5 cm and diameter 4.5 cm) was sub-
merged 1–1.5 cm below the surface of the water. The test
was performed three times a day for 6 days during the acqui-
sition phase (days 1–6), with three randomized starting points.
The position of the escape platform was kept constant. Each
trial lasted for 60 s or ended as soon as the mice reached the
submerged platform. The swimming pattern of each mouse
was monitored and recorded by a camera mounted above the
center of the pool, and the escape latency, escape distance, and
swimming speed were assessed by the SMART-LD program
(Panlab, Barcelona, Spain). A quiet environment, consistent
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lighting, constant water temperature, and a fixed spatial frame
were maintained throughout the experimental period.
Probe Test
To assess memory consolidation, a probe test was performed
48 h after the water maze test (i.e., day 8). For the probe test,
the platform was removed from the pool, and the mice were
allowed to swim freely. The swimming pattern of each mouse
was monitored and recorded for 60 s using the SMART-LD
program (Panlab). Consolidated spatial memory was estimat-
ed by the time spent in the target quadrant area.
Passive Avoidance Test
The passive avoidance response was determined using a
“step-through” apparatus (Med Associates, Georgia, VT,
USA). Forty-eight hours after the probe test (i.e., day 10), a
training trial was performed. After the training trial, each
mouse was placed in the illuminated compartment of the
apparatus facing away from the dark compartment. When
the mouse moved completely into the dark compartment, it
received an electric shock (0.4mA, 3-s duration). Twenty-four
hours after the training trial (i.e., day 11), each mouse was
placed in the illuminated compartment, and the latency period
until it entered the dark compartment was determined and
defined as the step-through latency. The cutoff time for the
examination was 180 s.
Collection and Preservation of Brain Tissues
After the passive avoidance test, mice were anesthetized with
diethyl ether and then perfused with phosphate-buffered saline
(PBS). The brains were immediately removed from the skull,
and the cortex and hippocampus were dissected on ice. All
brain tissues were stored at −80 °C until biochemical analysis.
Immunohistochemical Staining
After being anesthetized with diethyl ether, subgroups of mice
were perfused intracardially with 50 ml saline. The brains
were taken out from the skull and post-fixed in 4 % parafor-
maldehyde for 24 h at 4 °C. The brains were transferred to
30 % sucrose solutions. Subsequently, brains were cut into
25-μm sections by using a cryostat microtome (Leica
CM1850; Leica Microsystems, Seoul, Korea). After multiple
washes in PBS, endogenous peroxidase activity was quenched
by incubating the samples in 3 % hydrogen peroxide in PBS
for 30 min, followed by a 10-min wash in PBS. The sections
were then incubated for 2 h at room temperature with a rabbit/
mouse polyclonal antibody against glial fibrillary acidic pro-
tein (GFAP), inducible nitric oxide synthase (iNOS), receptor
for advanced glycation end products (RAGE) (1:300; Abcam,
Inc, Cambridge, MA, USA), a rabbit polyclonal antibody
against cyclooxygenase-2 (Cox-2), and Aβ (1:300; Cell
Signaling Technology, Inc., Beverly, MA, USA). After incu-
bation with the primary antibodies, sections were washed in
PBS before being incubated for 1 h at room temperature in the
presence of biotinylated goat anti-rabbit or anti-mouse
IgG secondary antibodies (1:1,000; Vector Laboratories,
Burlingame, CA, USA). Sections were then washed with
PBS and incubated with avidin–peroxidase complex (Vector
Laboratories, Burlingame, CA, USA) for 30 min before the
immunocomplex was visualized using the chromogen 3,3′-
diaminobenzidine (Vector Laboratories, Burlingame, CA,
USA). Sections were then counterstained with hematoxylin.
Finally, sections were dehydrated in ethanol, cleared in xy-
lene, and covered with Permount. Immunohistochemical
staining was performed on eight mice per group.
Western Blot Analysis
The brain and liver tissues were homogenized with lysis
buffer (PRO-PREP; iNtRON, Seongnam, Korea; n=8 mice
per group) and centrifuged at 2,500×g for 15 min at 4 °C.
Equal amounts of total protein (40 μg) isolated from the
hippocampus regions of brain tissues were resolved on 8 or
10 % sodium dodecyl sulfate polyacrylamide gels and then
transferred to nitrocellulose membranes (Hybond ECL;
Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Membranes were incubated at room temperature for 2 h with
the following specific antibodies: anti-GFAP, anti-RAGE
(both 1:1,000; Abcam, Inc, Cambridge, MA, USA),
anti-Cox-2, anti-β-secretase (BACE) 1 (Cell Signaling
Technology, Inc., Beverly, MA, USA), anti-NEP, anti-iNOS,
anti-amyloid precursor protein (anti-APP) (1:1,000, Novus
Biologicals, Inc., Littleton), anti-BAX, anti-caspase-3, anti-
lipoprotein receptor-related protein (LRP), anti-matrix metal-
loproteinase (MMP)-9 (1:1,000; Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), and anti-β-actin (1:2,500;
Sigma, St Louis, MO, USA). Blots were then incubated at
room temperature for 2 h with corresponding peroxidase-
conjugated anti-mouse or anti-rabbit antibodies (1/2,000;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA).
Immunoreactive proteins were detected using an enhanced
chemiluminescence [7] Western blotting detection system.
The relative density of the protein bands was scanned
densitometrically using My Image (SLB, Seoul, Korea) and
quantified by Lab Works 4.0 (UVP, Upland, CA, USA).
Measurement of Aβ1–40 and Aβ1–42
Lysates of brain tissue were obtained through protein extrac-
tion buffer containing protease inhibitor. Aβ1–40 and Aβ1–42
levels were determined using each specific ELISA Kit
(Immuno-Biological Laboratories Co., Ltd., Takasaki-Shi,
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Gunma, Japan). In brief, 100 μl of sample was added into a
precoated plate and incubated overnight at 4 °C. After wash-
ing each well of the precoated plate with a washing buffer,
100 μl of labeled antibody solution was added, and the mix-
ture was incubated for 1 h at 4 °C in the dark. After washing,
chromogen was added, and the mixture was incubated for
30 min at room temperature in the dark. Finally, the resulting
color was assayed at 450 nm using a microplate absorbance
reader (Sunrise™, Tecan, Switzerland) after adding stop
solution.
Thioflavin S Staining
The brains were taken out from the skull and post-fixed in 4 %
paraformaldehyde for 24 h at 4 °C. The brains were transferred
to 30 % sucrose solutions. Subsequently, brains were cut into
25-μm sections by using the cryostat microtome (Leica
CM1850; Leica Microsystems, Seoul, Korea). The sections
of the brain were thoroughly washed with distilled water for
5 min and then transferred to gelatin-coated slices and placed
in 1 % thioflavin S for 5 min. After this, the sections were
washed in distilled water then dehydrated through ascending
grades of ethanol, 50, 70, 90, and 100 % ethanol for 2 min in
each grade. The sections were then mounted in a mounting
medium (Fluoromount™ Aqueous Mounting Medium,
Sigma, St Louis, MO, USA). The thioflavin S staining was
examined using a fluorescence microscope. Thioflavin stain-
ing was performed on eight mice per group.
Assay of Neprilysin Activities
Five randomly chosen mice from each group were examined.
Neprilysin activities were determined using a neprilysin ac-
tivity assay kit (CBA079, Calbiochem, Darmstadt, Germany)
according to the manufacturer’s protocols. Briefly, brains
(hippocampus regions) were homogenized in 50-mM potas-
sium phosphate buffer, pH 7.3, containing a proteinase inhib-
itor mix (Sigma, St Louis, MO, USA). Samples were centri-
fuged, and the supernatant fraction was used for neprilysin
activity measurement. The hydrolysis of fluorogenic substrate
peptides (2 mM Mca-RPPGFSAFKDNP-OH, R&D system,
no. ES005) in 20-mM potassium phosphate buffer, pH 7.3)
was measured by following an increase in fluorescence
(exCitation at 320 nm and emission at 405 nm) that occurred
upon peptide bond cleavage for neprilysin activity. The
neprilysin activities were indicated as nanomole (obtained
from a standard curve using a fluorescence unit) per micro-
gram of protein per minute.
Assay of β-Secretase Activities
β-Secretase activity in mice brains was determined using a
commercially available β-secretase activity kit (Abcam, Inc,
Cambridge, MA, USA). Protein was extracted from
brain tissues (hippocampus regions) using ice-cold ex-
traction buffer, incubated on ice for 20 min and centri-
fuged at 10,000×g for 5 min at 4 °C. The supernatant
was collected. A total of 50 μl of sample (total protein
100 μg) was added to each well followed by 50 μl of
2×reaction buffer and 2 μl of beta-secretase substrate
incubated in the dark at 37 °C for 2 h. Fluorescence
was read at excitation and emission wavelengths of 355
and 510 nm, respectively, using a Fluostar Galaxy fluo-
rimeter (BMG Lab Technologies, Offenburg, Germany)
with Felix software (BMG Lab Technologies, Offenburg,
Germany). Beta-secretase activity is proportional to the fluo-
rimetric reaction and is expressed as nanomole per milligram
of protein per minute.
Cresyl Violet Staining
The brains were taken out from the skull and post-fixed in 4 %
paraformaldehyde for 24 h at 4 °C. The brains were trans-
ferred to 30 % sucrose solutions. Subsequently, brains were
cut into 25-μm sections by using the cryostat microtome
(Leica CM1850; Leica Microsystems, Seoul, Korea). The
brain sections were thoroughly washed with PBS to remove
the excess fixative agent and then transferred to gelatin-coated
slices and stained with 0.1 % cresyl violet (2–5 min) for the
purpose of identifying cortical layers and cytoarchitectural
features of the isocortical region. After this, the sections were
washed in distilled water and then dehydrated through ascend-
ing grades of ethanol, 50, 70, 90, and 100 % ethanol for 2 min
in each grade followed by a 10-min immersion in a 1:1
mixture of absolute alcohol and xylene. They were
cleared in xylene for 5–10 min and mounted in a
mounting medium (CYTOSEAL™ XYL; Thermo
Scientific, Pittsburgh, CO, USA). Cresyl violet staining
was performed on eight mice per group. For tissue measure-
ments and counting, the tissues were photographed in the
same areas. The positive neurons in each section were manu-
ally counted per 1-mm length area under ×200 magnification
by light microscopy.
Statistical Analysis
All statistical analysis was performed with GraphPad
Prism 4 software (Version 4.03; GraphPad software,
Inc., San Diego, CA, USA). Group differences in the
escape distance, latency, and velocity in the Morris
water maze task were analyzed using t test repeated
measures, the factors being treatment and testing day.
Otherwise, differences were analyzed by two-way
ANOVA followed by Dunnett’s post hoc test. All values
are presented as mean±S.E.M. Significance was set at
P<0.05 for all tests.
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Results
Effect of Knockout of ERα on Memory Impairment
Knockout of ERα mice and C57BL/6 wild-type mice was
infused with Aβ1–42 (300 pmol/day/mouse) for 2 weeks and
then compared for memory deficiency with saline-infused
C57BL/6 wild-type mice using the Morris water maze and
passive avoidance tests. All mice were trained for three trials
per day for 6 days. Escape latency and escape distances which
are the time and distance travelled to reach platform in water
maze were measured to determine the effect of knockout of
ERα on memory impairment. The mice exhibited shorter
time and shorter escape latency through the training;
however, the escape latency of Aβ1–42-infused mice in
both knockout of ERα mice and C57BL/6 wild-type
mice was not significantly reduced compared to the
saline-infused C57BL/6 wild-type mice, especially in
knockout of ERα mice. Statistical analysis of data from
days 1, 2, 4, and 6 showed that Aβ1–42-infused knock-
out of ERα mice has more memory impairment than
Aβ1–42-infused C57BL/6 wild-type mice. Escape distance at
the fourth and sixth day of the Aβ1–42-infused knockout of the
ERα mice group was longer than that of the Aβ1–42-infused
C57BL/6 wild-type mice group (Fig. 1a). Escape latency was
also increased in the Aβ1–42-infused knockout of the ERα
mice group (Fig. 1b). However, there was no significant
difference in average speed between the Aβ1–42-infused
knockout of the ERα mice group and the Aβ1–42-infused
C57BL/6 wild-type mice group (data not shown).
After the water maze test, we performed a probe test to
investigate the maintenance of memory. However, the time
spent in the target quadrant by infusion of Aβ1–42 has de-
creased in knockout of the ERα mice group (16.24±1.08 s)
compared with the Aβ1–42-infused C57BL/6 wild-type mice
(11.42±4.25 s) during the probe test. The probe test of the
Aβ1–42-infused knockout of the ERα mice group was shorter
than that of the Aβ1–42-infused C57BL/6 wild-type mice
group (Fig. 1c).
We next evaluated the learning and memory capacities by
the passive avoidance test using the step-through method. The
passive avoidance test of the Aβ1–42-infused knockout of the
ERα mice group was shorter than that of the Aβ1–42-infused
C57BL/6 wild-type mice group (Fig. 1d). There was no sig-
nificant difference in the learning trial. However, in the test
trial, infusion of Aβ1–42 decreased the step-through latency,
and infusion with Aβ1–42 (60.89±22.4 s) in the knockout of
ERα mice greatly decreased the step-through latency com-
pared with the Aβ1–42-infused C57BL/6 wild-type mice
(121.2±33.58 s).
Fig. 1 Effect of ERα knockout on memory impairment, Training trial
was performed three times a day for 6 days. Swimming distance (a) and
swimming time (b) to arrive at the platform were automatically recorded.
One day after training trials, a probe test was performed. The time spent in
the target quadrant and target site crossing within 60 s were represented
(c). To perform the passive avoidance test, the mice were given electric
shock when they entered into the dark compartment for training on
learning day. After 1 day, the retention time in illuminated step-through
test compartment was recorded (d). Each value is presented as mean±
S.E.M. from eight mice. An asterisk indicates a significant difference
between saline-infused and Aβ-infused mice (P<0.05). A number sign
indicates a significant difference betweenAβ-infusedC57BL/6wild-type
mice and Aβ-infused ERα KO mice (P<0.05)
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Effect of ERα Knockout on Cell Death in ERα Knockout
Mouse Brain
Cresyl violet staining was used to examine the survival
neurons. Neuronal cells were stained with cresyl violet
clearly in saline-infused C57BL/6 mice, but not well
defined in Aβ1–42-infused C57BL/6 wild-type mice and
ERα knockout mice (Fig. 2a). The numbers of viable neu-
rons per 1-mm length of cornu ammonis 3 (CA3) neuronal
cells (% of cresyl-violet-stained area) were quantitatively an-
alyzed. Survival of neuronal cells (51.93±1.67 %) in knock-
out of ERα mice greatly decreased compared with the
Aβ1–42-infused C57BL/6 wild-type mice (82.34±2.4 %)
(Fig. 2b). Western blot data for BAX and caspase-3(a pro-
apoptotic protein) expression (Fig. 2c) were also increased
in Aβ1–42-infused ERα knockout mice brain compared
to the expression in Aβ1–42-infused C57BL/6 wild-type
mice brain.
Enhancement Effect of ERα Knockout on Aβ Accumulation
and Amyloidogenesis
Several studies reported that the accumulation of Aβ in
the brain is the major causing factor in the development
of AD. So, we examined Aβ accumulation in both
Aβ1–42-infused ERα knockout mice and C57BL/6
wild-type mice. The immunohistochemical analysis by
an Aβ42-specific antibody has shown the Aβ deposition
in the cortex and hippocampus regions of Aβ1–42-in-
fused ERα knockout mice and C57BL/6 wild-type mice.
However, accumulation of Aβ in the brain of Aβ1–42-
infused ERα knockout mice was much higher compared
to the Aβ1–42-infused C57BL/6 wild-type mice brain
(Fig. 3a). In addition, we confirmed the higher accumu-
lation of Aβ in the brains of Aβ1–42-infused ERα
knockout mice by thioflavin S staining (Fig. 3b). To
determine whether Aβ deposition by immunohistochem-
ical analysis was paralleled with Aβ protein level in the
brain tissue, quantitative analyses of Aβ1–42 levels were
performed using an Aβ1–42-specific ELISA kit. Aβ1–42
levels in the brains of Aβ1–42-infused ERα knockout
mice were significantly higher compared to the levels of
Aβ1–42 in the Aβ1–42-infused C57BL/6 wild-type mice
brain (Fig. 3c). In addition, to evaluate BACE activity,
we performed Western blot analysis APP and BACE1
and β-secretase activity assay using a commercially avail-
able β-secretase activity kit. Western blot analysis also re-
vealed that APP and BACE1 expression were significantly
higher in the brains of Aβ1–42-infused ERα knockout mice
compared to Aβ1–42-infused C57BL/6 wild-type mice
Fig. 2 Effect of ERα knockout on cell death in a mouse brain. Neuronal
cells were stained with cresyl violet (a). The graph represents quantitation
of the number of neuronal cells (b). Total cell number counted × 200. All
values are the means±S.E. from three mice brains. An asterisk indicates a
significant difference between saline-infused to Aβ-infused mice
(P<0.05). A number sign indicates a significant difference between
Aβ-infused C57BL/6 wild-type mice and Aβ-infused ERα KO mice
(P<0.05)
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(Supplementary Fig. 2a). And, β-secretase activity was sig-
nificantly increased by the absence of ERα in the Aβ1–42-
infused brain (Supplementary Fig. 2b).
Effect of ERα Knockout on the Expression of Cox-2, iNOS,
and GFAP
We previously found that neuroinflammation is critical for Aβ
generation, and astrocytes are important neuronal cells con-
tributing to neuroinflammation and amyloidogenesis. To de-
termine whether ICVadministration with Aβ can also induce
neuroinflammation, and activation of astrocytes, we used the
methods of Western blot and immunohistochemistry to detect
the expression of Cox-2, iNOS, and GFAP in mouse brains
(Fig. 4a, b). Our data indicate that Aβ1–42-infused ERα
knockout mice significantly increase these proteins’ expres-
sion in the hippocampus and cortex when compared with
Aβ1–42-infused C57BL/6 wild-type mice. Immunostaining
for Cox-2, iNOS, and GFAP (a marker of astrocyte activation)
(Fig.4a) also showed a significantly higher number of Cox-2,
iNOS, and GFAP reactive cells in Aβ1–42-infused ERα
knockout mice brain compared to the number in Aβ1–42-
infused C57BL/6 wild-type mice brain.
Effect of ERα Knockout on the Expression of Neprilysin
and Activities of Neprilysin
We studied the activity of Aβ-degrading peptidase neprilysin
for studying possible causes of elevated levels of Aβ1–42 in
the Aβ1–42-infused ERα knockout mice brain since neprilysin
has an estrogen response element promoter region [15].
Decreased neprilysin reactive cell number (Fig. 5a) and ex-
pressions of neprilysin (Fig. 5b) were found in Aβ1–42-infused
ERα knockout mice brain. Agreement with enhanced expres-
sion of these proteins, the activities of neprilysin were also
significantly decreased in Aβ1–42-infused ERα knockout
mice brain (Fig. 5c). The accumulation of Aβ1–42 can also
be influenced by the influx of Aβ1–42 into the brain through a
RAGE in the brain. We determined RAGE expression by
immunohistochemical analysis (Supplementary Fig. 1a) and
by Western blotting (Supplementary Fig. 1b). But, expres-
sions of RAGE between the two groups are unclear.
Fig. 3 Effect of ERα knockout on the Aβ accumulation and Aβ level in
mouse brain. Immunostaining of amyloid-β protein in the hippocampus
was performed in 30-μm-thick sections of ERα knockout brain with anti-
Aβ1–42 primary antibody and the biotinylated secondary antibody (a).
Thioflavin S staining for detection of Aβ accumulation. The arrow in the
graph represents immunoreactive β-amyloid reactive cells in the mice
brain (b). Inhibitory effect of ERα knockout on the level of Aβ1–42 in
brain hippocampus (c) and cortex (d) detected by the ELISA method.
Values were mean±S.D. of eight mice. An asterisk indicates a significant
difference between saline-infused and Aβ-infused mice (P<0.05). A
number sign indicates a significant difference between Aβ-infused
C57BL/6 wild-type mice and Aβ-infused ERα KO mice (P<0.05)
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Effect of ERα Knockout on the Expression of MMP-9
and LRP-1 in ERα Knockout Mouse Liver
Since liver is another tissue involving systemic elimination of
Aβ1–42 in the blood through LRP-1, we determined LRP-1 in
the liver. MMP-9 is also critical for the degradation of Aβ in
the liver, so we also detected MMP-9 expression. Expression
of LRP-1 and MMP-9 was lowered in the Aβ1–42-infused
ERα knockout mice liver (Supplementary Fig. 1c). These data
indicate that a decreased degradation and/or clearance of
Aβ1–42 in the liver are related with increased Aβ1–42 accu-
mulation in an Aβ1–42-infused ERα knockout mice brain.
Discussion
Our present data showed that an intracerebroventricular infu-
sion of Aβ1–42 caused worsened memory impairment and
amyloidogenesis as well as neuroinflammation in ERα
knockout mice compared to the Aβ1–42-infused C57BL/6
wild-type mice. The worsened memory impairment in the
ERα knockout mice was associated with elevated Aβ level,
astrogliosis and neuroinflammation, and apoptotic neuronal
cell death in the brain. It was also found that the expression
and activities of neprilysin in the brain and expression of LRP
and MMP-9 in the liver of the ERα knockout mice were
significantly lowered. These data indicate memory impair-
ment in the ERα knockout mice through accumulation of
Aβ via reduced degradation and scavenging of Aβ by the
reduced expression and activity of neprilysin. Thus, it is clear
that knockout of ERα promotes worsened memory function.
Several ways could be explained as to the possible mech-
anisms in the worsenedmemory impairment in ERα knockout
mice. The accumulation of Aβ in the brain may be a signif-
icant contributor in the memory impairment in the ERα
knockout mice. A hypothesis that Aβ accumulation is closely
associated with the development of AD in animal models as
well as human patients [16, 17], we found significantly higher
accumulation of Aβ in the brains of ERα knockout mice.
Thus, the higher accumulation of Aβ in the brain of ERα
Fig. 4 Effect of ERα knockout on the activation of astrocytes and the
expression of Cox-2 and iNOS in mouse brain. The sections of mouse
brain incubated with anti-GFAP, Cox-2, and iNOS primary antibody and
the biotinylated secondary antibody (n=3). The representative stained
tissues were viewed with a microscope (×50 or 200) (a). Expression of
GFAP, Cox-2, and iNOS were also examined by specific antibodies in the
brain hippocampus (b). Each blot is representative for three mice
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knockout mice could result in worsened memory dysfunction.
Interestingly, the present study also showed that cell death,
Aβ accumulation, and neuroinflammation were clearer in the
CA3 region than in other brain regions. Recent study indicated
that estrogen effects on hippocampal neurons are more pro-
nounced in the CA3 region. There is also higher expression of
ERα in the CA3 region than in other regions of the
hippocampus including CA1 and DG [18]. This evidence
supported the more significant effect of estrogen on the CA3
region.
Accumulation of Aβ1–42 levels is due to decreased Aβ
clearance through the inhibition of the degradation in the brain
and/or decrease of efflux from the brain. Neprilysin, a major
endopeptidase involved in proteolysis-related degradation of
Fig. 5 Effect of ERα knockout on the expression and activity of
neprilysin in mouse brain. The representative stained tissues were viewed
with a microscope (×50 or 200) (a). Tissue lysates frommouse brain were
probed with Aβ-degrading peptidases, neprilysin protein antibodies,
respectively. Experiments were performed with three mouse brains (b).
Neprilysin activities were measured in the brains as mentioned in the
“Material and Methods”. All values are the means±S.E. from eight mice
brains (c). An asterisk indicates a significant difference between saline-
infused and Aβ-infused mice (P<0.05). A number sign indicates a
significant difference between Aβ-infused C57BL/6 wild-type mice and
Aβ-infused ERα KO mice (P<0.05)
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Aβ in the brain, is important in the clearance of Aβ [19]. In
the present study, we found that the expression and activities
of neprilysin were decreased in the Aβ1–42-infused ERα
knockout mice. It is noteworthy that the activity of neprilysin
is lower in AD patients [5, 10] and in ovaritectomized animals
[20]. Moreover, neprilysin has two EREs, and its activity can
be elevated by estrogen [21]. In present study, RAGE expres-
sion in the brain has no significant difference between ERα
WT with ERα KO mice. Similar to RAGE, expressions of
LRP-1 and MMP-9 have also no significant difference (data
not shown). But, expression of LRP-1 was significantly de-
creased in ERα knockout mice liver. The rapid peripheral
clearance of Aβ is mediated mainly by hepatic LRP-1 [22].
Reduced hepatic LRP-1 levels are associated with decreased
peripheral Aβ clearance [23]. These data indicate that Aβ
peptide degradation from the brain was prevented in the
Aβ1–42-infused ERα knockout mice through a decrease
of neprilysin activity. Expression of LRP-1, a clearance
receptor protein, was also decreased in the Aβ1–42-infused
ERα knockout mice liver. It should be known that down-
regulation of LRP-1 in older mice is associated with Aβ
accumulation in AD brains [24]. In our previous study, an
AD mouse (APPsw mice) brain showed lower expression
level of LRP-1 compared to a non-transgenic mouse brain
[25]. We also found that MMP-9 was lowered in the Aβ1–42-
infused ERα knockout mice. It was reported that estrogen
activates MMP-9 thus increasing Aβ degradation [26].
Several studies have demonstrated that estrogen could stimu-
late Aβ degradation enzymes such as MMP in vivo and
in vitro systems [26–28] as well as scavenger enzyme [29].
These data indicate that prevention systemic elimination
through liver LRP-1 and MMP-9 could play at least a role in
the increase of Aβ accumulation. Our present study suggests
that impairment of multiple clearance mechanisms is involved
in the accumulation of Aβ in the Aβ1–42-infused ERα knock-
out mice brain, thus affecting worsened memory impairment.
Astrocyte cells are important for the development of AD
because they are highly reactive to environmental changes,
such as oxidative stress and neuroinflammation [30]. Higher
activation of astrocytes releases many soluble factors such as
ROS, NO, PGs, TNF-α, and IL-1β which are critical for
neuronal cell death [31]. Several studies also reported that
Aβ can directly activate astrocytes [27, 32], which could
contribute to the Aβ-induced neuronal cell death in vitro
and in vivo [33]. Thus, worsened memory impairment in
Aβ1–42-infused ERα knockout mice by accumulation of Aβ
could be related with neuronal cell death via increased
astrogliosis and neuroinflammation. In the present study, ac-
tivation of astrocytes was greatly increased in the Aβ1–42-
infused ERα knockout compared to the Aβ1–42-infused
C57BL/6 wild-type mice. The activated astrocytes are pre-
dominant features of the inflammatory response in the brain of
AD and contribute to neuronal cell death. We also found
higher elevation of neuroinflammation evidenced by increased
expression of iNOS and Cox-2, accompanied with elevation of
GFAP expression. In response to brain injury, astrocytes become
reactive and express various inflammatory mediators that play
important roles in the secondary injury causing neuronal cell
death. In this regard, we found that the expression of pro-
apoptotic proteins such as Bax and caspase-3 was increased in
the Aβ1–42-infused ERα knockout mice brain. It was also found
that neuronal cell death was greatly increased in the Aβ1–42-
infused ERα knockout mice brain compared to the Aβ1–42-
infused C57BL/6 mice brain. These data indicate that accumu-
lation of Aβ in ERα knockout mice resulted in the activation of
astrocyte and neuroinflammation, thus causing neuronal cell
death leading to worsened memory impairment. Although there
is clear significance of ERα and ERβ in the protective role of
estrogen in theADdevelopment [5, 10, 20], theWomen’s Health
Initiative found that estrogen therapy on cognitive function for
post-menopausal women is no longer a benefit for treatment [3,
4]. Thus, clearer mechanistic roles of estrogen in the develop-
ment of AD should be further studied.
In conclusion, our data showed that infusion of Aβ1–42 in the
mice brain of ERα knockout definitely decreases memory func-
tions via an increase of astrogliosis and neuroinflammation-
related neuronal cell death through diminished Aβ elimination.
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